Search clinical trials for: CD30 CAR

Total 187691 results

Assiut University

Not yet recruiting

Intravenous Labetalol vs Phentolamine for the Management of Severe Preeclampsia.

Severe Pre-eclampsia
Sun Yat-sen University

Active, not recruiting

Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
St. Anna Kinderkrebsforschung

Unknown

ALL-SCT BFM International- HSCT in Children and Adolescents With ALL (ALL-SCT-BFMi)

Lymphoblastic Leukemia, Acute, Childhood;

Israel, Austria, Czech Republic, Denmark, France, Italy, Netherlands, Poland, Slovakia, Sweden, Turkey
Shenzhen Geno-Immune Medical Institute

Unknown

Combination CAR-T Cell Therapy Targeting Hematological Malignancies

B-cell Malignancies

China
Southwest Hospital, China

Unknown

A Clinical Research of CD30-Targeted CAR-T in Lymphocyte Malignancies

Lymphoma | Leukemia

China
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC

Completed

SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma

Lymphoma

United States
Centre Henri Becquerel

Completed

Kinetic of Cytokines Decrease and Hodgkin Lymphoma Prognostic (CYTOKINES-LH)

Hodgkin's Disease

France
UNC Lineberger Comprehensive Cancer Center
National Heart, Lung, and Blood Institute (NHLBI)

Active, not recruiting

Administration of T Lymphocytes for Prevention of Relapse of Lymphomas

Neoplasms | Immune System Diseases | Neoplasms by Histologic Type | Lymphoma | Lymphoproliferative Disorders | Lymphatic Diseases | Immunoproliferative Disorders | Lymphoma, Non-Hodgkin | Hodgkin Disease

United States
UNC Lineberger Comprehensive Cancer Center
Seagen Inc.

Active, not recruiting

BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma

Lymphoma | Lymphatic Diseases | Adult T-Cell Leukemia/Lymphoma

United States
Huazhong University of Science and Technology
The First Affiliated Hospital of Nanchang University

Recruiting

Camrelizumab Combined With CD30 CAR-T in the Treatment of Relapsed/Refractory CD30+ Lymphoma

Lymphoma | Relapse/Recurrence

China
UNC Lineberger Comprehensive Cancer Center
University Cancer Research Fund at Lineberger Comprehensive Cancer Center

Recruiting

CD30 CAR for CD30+ NSGCT

Nonseminomatous Germ Cell Tumor | Germ Cell Tumor

United States
Baylor College of Medicine
The Methodist Hospital Research Institute

Withdrawn

Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in Relapsed or Refractory CD30-Positive Lymphomas

Classical Hodgkin Lymphoma | Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type

United States
UNC Lineberger Comprehensive Cancer Center
American Society of Clinical Oncology

Recruiting

Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma

Refractory Hodgkin Lymphoma | Relapsed Hodgkin Lymphoma

United States
UNC Lineberger Comprehensive Cancer Center

Recruiting

CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma

Peripheral T Cell Lymphoma

United States
UNC Lineberger Comprehensive Cancer Center
Stand Up To Cancer; University Cancer Research Fund at Lineberger Comprehensive...

Recruiting

Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL

Neoplasms | Immune System Diseases | Lymphoma | Lymphoproliferative Disorders | Lymphatic Diseases | Immunoproliferative Disorders | Mycosis Fungoides | Sezary Syndrome | Cutaneous T Cell Lymphoma | Gray Zone Lymphoma | Cutaneous Lymphoma | Lymphomatoid Papulosis | Cutaneous Anaplastic Large Cell Lymphoma

United States
UNC Lineberger Comprehensive Cancer Center

Recruiting

Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL

Neoplasms | Immune System Diseases | Neoplasms by Histologic Type | Lymphoma | Lymphoproliferative Disorders | Lymphatic Diseases | Immunoproliferative Disorders | Lymphoma, Non-Hodgkin

United States
Seagen Inc.

Active, not recruiting

A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

Peripheral T-cell Lymphoma

United States, Czechia, Italy, Spain, United Kingdom, France
Tessa Therapeutics

Active, not recruiting

Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma (CERTAIN)

Anaplastic Large Cell Lymphoma | Diffuse Large B Cell Lymphoma | Peripheral T Cell Lymphoma | Extranodal NK/T-cell Lymphoma | Primary Mediastinal Large B-Cell Lymphoma (PMBCL)

United States
Baylor College of Medicine
The Methodist Hospital Research Institute

Recruiting

Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas

Classical Hodgkin Lymphoma | Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type

United States
Wuhan Union Hospital, China
Wuhan Bio-Raid Biotechnology Co, Ltd. China

Unknown

Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies

Hodgkin Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Peripheral T Cell Lymphoma | NK/T-cell Lymphoma | Adult T-Cell Lymphoma/Leukaemia

China
Peking University
University of Florida

Unknown

CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273)

Lymphomas

China, United States
Eric Bernicker, MD
Millennium Pharmaceuticals, Inc.; The Methodist Hospital Research Institute

Withdrawn

Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies (AD3LE)

CD30-positive Lymphoma | CD30-positive Solid Tumor

United States
Beijing Children's Hospital

Enrolling by invitation

BV-AVD-R Treatment Children Hodgkin's Lymphoma

Hodgkin Lymphoma

China
Ahmed Sawas

Completed

AFM13 in Relapsed/Refractory Cutaneous Lymphomas

Lymphoma, T-Cell, Cutaneous

United States
National Cancer Institute (NCI)

Completed

Phase I Study of HeFi-1 to Treat Cancers With CD30 Protein

Neoplasms

United States
Medical College of Wisconsin
Midwest Athletes Against Childhood Cancer

Not yet recruiting

CD30biAb-AATC for CD30+ Malignancies

Lymphoma | Leukemia | Hodgkin Disease | CD30-Positive Diffuse Large B-Cell Lymphoma | CD30+ Anaplastic Large Cell Lymphoma | CD30+ Pleomorphic Large T-Cell Cutaneous Lymphoma | CD30+ Immunoblastic Large T-Cell Cutaneous Lymphoma

United States
Chinese PLA General Hospital

Recruiting

CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas (CART30)

Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma

China
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Not yet recruiting

Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas

Hodgkin Lymphoma | Non-Hodgkin Lymphoma | Peripheral T-cell Lymphoma | Anaplastic Large Cell Lymphoma, ALK-Positive | Anaplastic Large Cell Lymphoma, ALK-negative | CD30-Positive Diffuse Large B-Cell Lymphoma | Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type

United States
Immune Cell, Inc.
Weifang People's Hospital

Recruiting

CD30 Targeted CAR-T in Treating CD30-Expressing Lymphomas

Hodgkin Lymphoma | Anaplastic Large Cell Lymphoma

China
Fondazione Italiana Linfomi ONLUS

Completed

Study on the Role of Brentuximab Vedotin as Single Agent in the Treatment of Relapsed/Refractory CD30+ PTCL Patients

Lymphatic Diseases

Italy
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Active, not recruiting

EBV CTLs Expressing CD30 Chimeric Receptors For CD 30+ Lymphoma (CARCD30)

Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma

United States
Baylor College of Medicine
The Methodist Hospital Research Institute

Recruiting

CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30) (RELY-30)

Hodgkin's Lymphoma | Non-Hodgkin Lymphoma

United States
UNC Lineberger Comprehensive Cancer Center

Not yet recruiting

ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells

Hodgkin Lymphoma | Relapse | Refractory

United States
Abramson Cancer Center of the University of Pennsylvania

Completed

Brentuximab Vedotin and Chemotherapy in CD30+ PMBL, Diffuse Large B-Cell, and Grey Zone Lymphoma Patients

CD30-Positive Diffuse Large B-Cell Lymphoma | CD30 Positive Primary Mediastinal Large B-cell Lymphoma | CD30-Positive Gray Zone Lymphoma

United States
National Cancer Institute (NCI)

Completed

T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas

Lymphoma, Large B-Cell, Diffuse | Lymphoma, T-Cell, Peripheral | Lymphoma, Large-Cell, Anaplastic | Lymphoma, Extranodal NK-T-Cell | Enteropathy-Associated T-Cell Lymphoma

United States
University of Cologne

Unknown

Multicentre Phase I Trial of Engineered T Cells for Patients With Relapsed or Refractory Primary Cutaneous CD30+ Large T Cell Lymphoma or Transformed CD30+ Mycosis Fungoides (TECLA)

CD30 Positive Cutaneous T Cell Lymphoma | CD30 Positive Transformed Mycosis Fungoides

Germany
Nabil Adra

Terminated

Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors

Nonseminomatous Germ Cell Tumor | Testis Cancer | Testicular Cancer | Embryonal Carcinoma | Germ Cell Tumors

United States
Fondazione Italiana Linfomi ONLUS

Terminated

Bendamustine Plus Brentuximab Vedotin in HL and CD30+ PTCL in First Salvage Setting (FIL-BBV)

Lymphatic Diseases

Italy
Fondazione Italiana Linfomi ONLUS

Completed

A Study of SGN-35 (Brentuximab Vedotin) of Patients With Relapsed or Refractory PMLBCL (FIL_SGN01)

Primary Mediastinal Large B Cell Lymphoma

Italy
Tessa Therapeutics

Active, not recruiting

Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)

Hodgkin Lymphoma, Adult | Hodgkin Disease Recurrent | Hodgkin Disease Refractory | Hodgkin Disease, Pediatric

United States
Czech Lymphoma Study Group

Not yet recruiting

Brentuximab Vedotin in Combination With CHEP in Patient With PTCL

Lymphoma, T-Cell, Peripheral

Czechia
Insel Gruppe AG, University Hospital Bern
Mundipharma Medical Company

Suspended

Brentuximab Vedotin and BeEAM High-dose Chemotherapy in Lymphomas (BAL)

Lymphoma

Switzerland
Zhejiang University
Shanghai First Song Therapeutics Co., Ltd

Not yet recruiting

An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma

Hodgkin Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Diffuse Large B Cell Lymphoma | Gray Zone Lymphoma | NK/T Cell Lymphoma | Peripheral T Cell Lymphoma, Unspecified | Mediastinal B-Cell Diffuse Large Cell Lymphoma

China
Virginia Commonwealth University
Seagen Inc.

Completed

TSEB and Brentuximab for Treatment of Mycosis Fungoides & Sezary Syndrome

Mycosis Fungoides | Sézary Syndrome

United States
University of Kansas Medical Center
Seagen Inc.

Recruiting

Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas (BRENTICON-T)

T Cell Lymphoma

United States
Seagen Inc.

Terminated

A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma

Hodgkin Lymphoma | Anaplastic Large Cell Lymphoma | Peripheral T Cell Lymphoma

United States
The First Affiliated Hospital of Soochow University
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

Unknown

CAR-T for R/R B-NHL

Refractory Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma | CAR - T CD19/CD20/CD22/CD30

China
Seagen Inc.

Completed

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Acute Myeloid Leukemia | Solid Tumors | Acute Lymphoid Leukemia | Anemia, Refractory, With Excess of Blasts

United States
Jason Robert Gotlib
Seagen Inc.

Completed

Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia

Systemic Mastocytosis | Mast Cell Leukemia | Aggressive Systemic Mastocytosis

United States
Bristol-Myers Squibb

Completed

A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease

Hodgkin's Disease

United States

Search clinical trials for: CD30 CAR

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations